S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NYSE:MRK

Merck & Co., Inc. (MRK) Stock Forecast, Price & News

$93.55
+1.46 (+1.59%)
(As of 05/20/2022 07:00 PM ET)
Add
Compare
Today's Range
$92.45
$94.08
50-Day Range
$78.12
$93.55
52-Week Range
$70.89
$94.56
Volume
11.76 million shs
Average Volume
12.24 million shs
Market Capitalization
$236.57 billion
P/E Ratio
16.74
Dividend Yield
2.95%
Beta
0.37
30 days | 90 days | 365 days | Advanced Chart
Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for Merck & Co., Inc. and its competitors with MarketBeat's FREE daily newsletter.

Merck & Co., Inc. logo

About Merck & Co., Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Headlines

COVID-19 treatment, Keytruda boost drugmaker Merck in Q1
Merck soared past first-quarter expectations, helped by sales of its long-standing blockbuster cancer drug Keytruda and a new COVID-19 treatment that also topped forecasts
Is Perrigo a Buy After Reporting Q1 Earnings?
Merck & Co Whale Trades For May 18
Merck (MRK) Shares Cross 3% Yield Mark
Merck & Co., Inc. (NYSE:MRK) Trading Down 1.4%
Analyzing Merck & Co's Short Interest
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
58933Y10
Employees
68,000
Year Founded
1891

Sales & Book Value

Annual Sales
$48.70 billion
Cash Flow
$7.43 per share
Book Value
$16.19 per share

Profitability

Net Income
$13.05 billion
Pretax Margin
29.18%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares
2,528,805,000
Free Float
2,521,471,000
Market Cap
$236.57 billion
Optionable
Optionable

Company Calendar

Ex-Dividend for 4/7 Dividend
3/14/2022
Dividend Payable
4/07/2022
Last Earnings
4/28/2022
Today
5/23/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.33 out of 5 stars

Medical Sector

247th out of 1,416 stocks

Pharmaceutical Preparations Industry

91st out of 677 stocks

Analyst Opinion: 1.3Community Rank: 4.5Dividend Strength: 4.2Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -













Merck & Co., Inc. (NYSE:MRK) Frequently Asked Questions

Is Merck & Co., Inc. a buy right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 7 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Merck & Co., Inc. stock.
View analyst ratings for Merck & Co., Inc.
or view top-rated stocks.

When is Merck & Co., Inc.'s next earnings date?

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Merck & Co., Inc.
.

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) released its quarterly earnings data on Thursday, April, 28th. The company reported $2.14 EPS for the quarter, topping the consensus estimate of $1.83 by $0.31. The firm earned $15.90 billion during the quarter, compared to analyst estimates of $14.64 billion. Merck & Co., Inc. had a trailing twelve-month return on equity of 47.86% and a net margin of 26.27%. Merck & Co., Inc.'s quarterly revenue was up 31.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.40 earnings per share.
View Merck & Co., Inc.'s earnings history
.

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Merck & Co., Inc. announced a quarterly dividend on Tuesday, January 25th. Investors of record on Tuesday, March 15th will be paid a dividend of $0.69 per share on Thursday, April 7th. This represents a $2.76 dividend on an annualized basis and a dividend yield of 2.95%. The ex-dividend date of this dividend is Monday, March 14th.
View Merck & Co., Inc.'s dividend history
.

Is Merck & Co., Inc. a good dividend stock?

Merck & Co., Inc. pays an annual dividend of $2.76 per share and currently has a dividend yield of 2.95%. Merck & Co., Inc. has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Merck & Co., Inc. is 49.37%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Merck & Co., Inc. will have a dividend payout ratio of 38.28% next year. This indicates that Merck & Co., Inc. will be able to sustain or increase its dividend.
View Merck & Co., Inc.'s dividend history.

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

Merck & Co., Inc. updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of $7.24-$7.36 for the period, compared to the consensus earnings per share estimate of $7.24. The company issued revenue guidance of $56.90 billion-$58.10 billion, compared to the consensus revenue estimate of $57.35 billion.

What price target have analysts set for MRK?

15 Wall Street analysts have issued twelve-month price objectives for Merck & Co., Inc.'s stock. Their forecasts range from $70.00 to $110.00. On average, they expect Merck & Co., Inc.'s share price to reach $91.27 in the next twelve months. This suggests that the stock has a possible downside of 2.4%.
View analysts' price targets for Merck & Co., Inc.
or view top-rated stocks among Wall Street analysts.

Who are Merck & Co., Inc.'s key executives?
Merck & Co., Inc.'s management team includes the following people:
What is Kenneth C. Frazier's approval rating as Merck & Co., Inc.'s CEO?

1,343 employees have rated Merck & Co., Inc. CEO Kenneth C. Frazier on Glassdoor.com. Kenneth C. Frazier has an approval rating of 94% among Merck & Co., Inc.'s employees. This puts Kenneth C. Frazier in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Merck & Co., Inc. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), Walt Disney (DIS), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and Home Depot (HD).

What is Merck & Co., Inc.'s stock symbol?

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Who are Merck & Co., Inc.'s major shareholders?

Merck & Co., Inc.'s stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.55%), BlackRock Inc. (8.07%), State Street Corp (4.68%), Wellington Management Group LLP (1.81%), Bank of New York Mellon Corp (1.30%) and Charles Schwab Investment Management Inc. (1.19%). Company insiders that own Merck & Co., Inc. stock include Caroline Litchfield, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Richard R Deluca, Rita A Karachun, Robert M Davis and Sanat Chattopadhyay.
View institutional ownership trends for Merck & Co., Inc.
.

Which major investors are selling Merck & Co., Inc. stock?

MRK stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, Wellington Management Group LLP, Bank of Nova Scotia, Toronto Dominion Bank, First Trust Advisors LP, Dimensional Fund Advisors LP, Robeco Institutional Asset Management B.V., and Bahl & Gaynor Inc.. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Caroline Litchfield, Frank Clyburn, Kenneth C Frazier, Richard R Deluca, Rita A Karachun, and Sanat Chattopadhyay.
View insider buying and selling activity for Merck & Co., Inc.
or view top insider-selling stocks.

Which major investors are buying Merck & Co., Inc. stock?

MRK stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Vanguard Group Inc., Caisse DE Depot ET Placement DU Quebec, Bank of New York Mellon Corp, Arrowstreet Capital Limited Partnership, Swiss National Bank, and Capital Wealth Planning LLC.
View insider buying and selling activity for Merck & Co., Inc.
or or view top insider-buying stocks.

How do I buy shares of Merck & Co., Inc.?

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Merck & Co., Inc.'s stock price today?

One share of MRK stock can currently be purchased for approximately $93.55.

How much money does Merck & Co., Inc. make?

Merck & Co., Inc. has a market capitalization of $236.57 billion and generates $48.70 billion in revenue each year. The company earns $13.05 billion in net income (profit) each year or $5.59 on an earnings per share basis.

How many employees does Merck & Co., Inc. have?

Merck & Co., Inc. employs 68,000 workers across the globe.

When was Merck & Co., Inc. founded?

Merck & Co., Inc. was founded in 1891.

What is Merck & Co., Inc.'s official website?

The official website for Merck & Co., Inc. is www.merck.com.

How can I contact Merck & Co., Inc.?

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at (908) 740-4000, via email at [email protected], or via fax at 908-735-1253.

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.